Company Filing History:
Years Active: 2013-2015
Title: The Innovative Contributions of Andreas Schreiner
Introduction
Andreas Schreiner is a notable inventor based in Rheinfelden, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of novel crystalline forms of compounds. With a total of 2 patents to his name, his work has implications for drug formulation and delivery.
Latest Patents
Schreiner's latest patents include the preparation of anhydrous and hydrated polymorphs of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one-lactic acid salt. This technology provides methods for creating anhydrous crystalline Form II and monohydrate crystalline Form B of the lactic acid salt. Another significant patent involves crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one lactic acid salts. This patent outlines methods for producing these polymorphs, as well as pharmaceutical compositions and treatment methods utilizing them.
Career Highlights
Andreas Schreiner is currently employed at Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to focus on innovative drug development, contributing to advancements in pharmaceutical science. His expertise in polymorph characterization has positioned him as a valuable asset in the industry.
Collaborations
Throughout his career, Schreiner has collaborated with several talented individuals, including Danielle Giron and Walter Hammerschmidt. These collaborations have fostered a creative environment that encourages innovation and the sharing of ideas.
Conclusion
Andreas Schreiner's contributions to the field of pharmaceuticals through his patents and work at Novartis AG highlight his role as an influential inventor. His innovative approaches to drug formulation continue to impact the industry positively.